Mogroside IV-E
Based on 1 publication(s) in Google Scholar
Mogroside IV-E is a PUS1 inhibitor that reduces PUS1 expression and inhibits bone metastasis of prostate cancer. Mogroside IV-E can be used in prostate cancer-related research.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 88915-64-4
- Formula: C54H92O24
- Molecular Weight:1125.29
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-diabetic Compound Library
HY-L040
-
Glycoside Compound Library
HY-L042
-
Terpenoids Library
HY-L056
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Mogroside IV-E
MoreAll DNA/RNA Synthesis Isoforms
More
Biological Activity
Mogroside IV-E (compound 3) (10-20 μM) dose-dependently reduces PUS1 protein expression in DU145 and PC-3 prostate cancer cells[1].
Mogroside IV-E (10-20 μM; 24 h) dose-dependently inhibits the migration and invasion of DU145 and PC-3 prostate cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human prostate cancer DU145 and PC-3 cells
-
Concentration:10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Inhibited the migration of DU145 and PC-3 prostate cancer cells.
-
Cell Line:human prostate cancer DU145 and PC-3 cells
-
Concentration:10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Inhibited the invasion of DU145 and PC-3 prostate cancer cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (4 to 5-week-old; bone metastasis model via tail artery injection of 2×106 PUS1 cells)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:i.p.
-
Result:Showed significant reduction in bone destruction compared to PBS control.
Demonstrated dose-dependent reductions in bone metastatic lesion fluorescence intensity: at week 6, achieved a mean bone metastasis BLI of ~200 (10 mg/kg group) and ~100 (20 mg/kg group), compared to ~600 in the PBS group.
Improved time to event survival with hazard ratios of 5.712 (PBS vs 10 mg/kg) and 7.344 (PBS vs 20 mg/kg).
Significantly decreased PUS1 expression in bone metastatic lesions.
Chemical Information
-
CAS No. 88915-64-4
-
Appearance Solid
-
Molecular Weight 1125.29
-
Formula C54H92O24
-
Color White to off-white
-
SMILES
C[C@]12[C@](CC=C3[C@@]2([H])CC[C@H](O[C@]4([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)CO[C@@H]5O[C@@H]([C@@H](O)[C@H](O)[C@H]5O)CO)C3(C)C)([H])[C@]6([C@@](C)([C@]([C@H](C)CC[C@H](C(C)(O)C)O[C@H]7[C@@H]([C@H]([C@H](O)[C@@H](CO)O7)O)O[C@]8([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]8O)CO)([H])CC6)C[C@H]1O)C
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Sci
FOXA1-dependent PUS1 regulates EIF3b stability in a non-enzymatic pathway mediating prostate cancer bone metastasis. [Abstract]2024 Aug 19;20(11):4566-4584. PMID: 39247811
Solvent & Solubility
DMSO : 100 mg/mL (88.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8887 mL | 4.4433 mL | 8.8866 mL | 22.2165 mL |
| 5 mM | 0.1777 mL | 0.8887 mL | 1.7773 mL | 4.4433 mL | |
| 10 mM | 0.0889 mL | 0.4443 mL | 0.8887 mL | 2.2216 mL | |
| 15 mM | 0.0592 mL | 0.2962 mL | 0.5924 mL | 1.4811 mL | |
| 20 mM | 0.0444 mL | 0.2222 mL | 0.4443 mL | 1.1108 mL | |
| 25 mM | 0.0355 mL | 0.1777 mL | 0.3555 mL | 0.8887 mL | |
| 30 mM | 0.0296 mL | 0.1481 mL | 0.2962 mL | 0.7405 mL | |
| 40 mM | 0.0222 mL | 0.1111 mL | 0.2222 mL | 0.5554 mL | |
| 50 mM | 0.0178 mL | 0.0889 mL | 0.1777 mL | 0.4443 mL | |
| 60 mM | 0.0148 mL | 0.0741 mL | 0.1481 mL | 0.3703 mL | |
| 80 mM | 0.0111 mL | 0.0555 mL | 0.1111 mL | 0.2777 mL |
Mogroside IV-E Related Classifications
HY-N2456 Related Classifications
Powered by Bioz